{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:21:49Z","timestamp":1767900109153,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.msard.2024.105737","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:02:23Z","timestamp":1719532943000},"page":"105737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7465-5749","authenticated-orcid":false,"given":"John Patrick","family":"Dempsey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Balshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursela","family":"Baber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-3031","authenticated-orcid":false,"given":"Jacob A.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11\u201312","key":"10.1016\/j.msard.2024.105737_bib0014","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1177\/13524585231189641","article-title":"High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate","volume":"29","author":"Balshi","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105737_bib0015","unstructured":"Biogen IDEC, Inc. (2013). Tecfidera\u2122 (dimethyl fumarate): Prescribing Information. Cambridge, MA."},{"key":"10.1016\/j.msard.2024.105737_bib0016","unstructured":"Biogen IDEC, Inc. (2019). Vumerity\u2122 (diroximel fumarate): Prescribing Information. Cambridge, MA."},{"issue":"Pt 9","key":"10.1016\/j.msard.2024.105737_bib0007","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2024.105737_bib0004","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3390\/cells10113177","article-title":"Lymphocyte Counts and Multiple Sclerosis Therapeutics: between Mechanisms of Action and Treatment-Limiting Side Effects","volume":"10","author":"Fischer","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.msard.2024.105737_bib0011","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2024.105737_bib0010","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2024.105737_bib0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000017903","article-title":"Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis","volume":"196","author":"H\u00f6xtermann","year":"1998","journal-title":"Dermatology (Basel)"},{"key":"10.1016\/j.msard.2024.105737_bib0001","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2024.105737_bib0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2024.105737_bib0012","unstructured":"National Cancer Institute. Common Terminology Criteria For Adverse Events v3.0 (CTCAE). 2006. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"10.1016\/j.msard.2024.105737_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104081","article-title":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","volume":"67","author":"Ravn","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105737_bib0006","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105737_bib0013","series-title":"Stata Statistical Software: Release 17","year":"2021"},{"key":"10.1016\/j.msard.2024.105737_bib0008","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Application 11855 Summary Review. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211855Orig1s000SumR.pdf."},{"issue":"4","key":"10.1016\/j.msard.2024.105737_bib0009","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: results from the Phase 3 EVOLVE-MS-1 Study","volume":"39","author":"Wray","year":"2022","journal-title":"Adv. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T19:20:37Z","timestamp":1724008837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":16,"alternative-id":["S2211034824003146"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105737","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105737"}}